Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz in Creutzfeldt-Jakob Disease
NCT07482085Phase 3Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Creutzfeldt-Jakob disease (CJD) comparing Efavirenz Treatment Arm with Placebo Control Arm (2 arms). Primary endpoint: Overall Survival at 36 months. Started Apr 2026; status: recruiting.
02
Drugs
efavirenz
03
Conditions
Creutzfeldt-Jakob disease (CJD)
Beyond the preview
Go deeper on NCT07482085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482085.